Indo US Bio-Tech Receives ED Summons Under PMLA for Inquiry Purposes

Indo US Bio-Tech Limited has informed stock exchanges about receiving summons from the Directorate of Enforcement (ED) under the Prevention of Money Laundering Act (PMLA), 2002. The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Summons Details

The company received the summons dated November 20, 2025, from the Directorate of Enforcement, Raipur Zonal Office. The summons was issued under Section 50(2) and 50(3) of the PMLA, 2002, requiring the appearance of the Principal Officer and production of specific information and documents for investigation purposes.

Nature of Action

According to the company's disclosure, the summons is for inquiry and investigative purposes. The company emphasized that no formal charges or orders have been passed against it. The enforcement action appears to be part of a routine investigation requiring document production and officer appearance.

Impact Assessment

Indo US Bio-Tech Limited stated that there is no immediate material impact expected on the company's financial or operational activities due to this summons. The company characterized this as an investigative inquiry rather than any punitive action.

Disclosure Timeline

The company acknowledged a delay in making this disclosure to the stock exchanges. The summons was dated November 20, 2025, and received on November 27, 2025, but the disclosure was made on December 29, 2025. The company attributed this delay to the time required for internal review of the summons and awaiting legal assessment to ensure accuracy of the disclosure, clarifying that the delay was not intentional.

The disclosure was signed by Mr. Jagdish Ajudia, Managing Director (DIN: 01745951), and submitted to both BSE Limited and National Stock Exchange of India Limited as required under regulatory compliance norms.